Close Menu

People in the News

Apr 02, 2020

10x Genomics: Kim Popovits

10x Genomics has appointed Kim Popovits to its board of directors. Popovits is the former chairman, president, and CEO of Genomic Health. She started at Genomic Health in 2002 as president and chief operating officer, before becoming CEO in 2009 and chairman in 2012. The company was acquired by Exact Sciences in November 2019.

Prior to joining Genomic Health, Popovits held several management roles at Genentech, including senior vice president of marketing and sales where she led the commercialization of 14 new therapies. In addition to her board position at 10x Genomics, Popovits is currently a member of the boards of Kiniksa Pharmaceuticals and MyoKardia, and previously served on the board of ZS Pharma.  

Apr 02, 2020

Castle Biosciences: Miles Harrison

Castle Biosciences has appointed Miles Harrison to its board of directors effective immediately, expanding the size of the board to eight members. Harrison will stand for election for a three-year term at the company's 2020 annual meeting of stockholders.

Since February 2016, Harrison as served as the North American president and general manager of independent global dermatology company Galderma Laboratories. He has also served as vice president and general manager of Galderma's consumer business unit. Prior to Galderma, Harrison spent most of his career at Novartis, and has held multiple leadership positions of increasing responsibility across the consumer, oncology and pharmaceuticals businesses, most recently as vice president and head of global advocacy.

Apr 01, 2020

Biotheranostics: Matt Sargent

Biotheranostics has promoted its vice president of sales, Matt Sargent, to the position of chief commercial officer. In his new role, Sargent will be responsible for sales, marketing, market access, and customer service, and will lead the company's growth of its core tests: Breast Cancer Index and CancerTYPE ID. Sargent holds over 17 years of experience in the oncology diagnostic space during which he led the launch of Breast Cancer Index at Biotheranostics and the launch of the oncology division of Caris Life Sciences, where he served as vice president of oncology sales.

Apr 01, 2020

LexaGene: Eleanor Kolossovski

LexaGene has appointed Eleanor Kolossovski as director of product marketing. Kolossovski most recently served as senior global product manager at Qiagen. She has also held multiple sales and marketing positions at clinical diagnostic firms including BD, Roche, and Qiagen. 

Mar 31, 2020

Flagship Biosciences: Geoff Metcalf

Flagship Biosciences announced the hiring of Geoff Metcalf as VP of clinical diagnostics, where he will lead the creation and implementation of diagnostic tissue tests. Metcalf has worked in product development, sales and marketing, and business development at companies including Eli Lilly and Beckman Coulter. Most recently he was head of strategic planning at Siemens Diagnostics.

Metcalf earned a bachelor's degree in chemical engineering from Virginia Tech and a master of business administration degree from Harvard.

Mar 26, 2020

LexaGene: Steven Armstrong

LexaGene has appointed Steven Armstrong as senior director of operations as part of the firm's plans to oversee its submission for US Food and Drug Administration Emergency Use Authorization of its commercial technology and other regulatory approvals. Armstrong's career includes obtaining FDA and global regulatory approvals in over 100 countries for more than 50 devices. 

Mar 25, 2020

Qiagen: Thierry Bernard

Qiagen said this week that it has named Thierry Bernard as CEO. Qiagen's board has also resolved to propose Bernard for election as CEO and managing director at the company's next annual meeting in June. Bernard, who is also senior VP and head of molecular diagnostics at Qiagen, has served as the company's interim CEO since October, when long-time CEO Peer Schatz parted ways with the company. Bernard joined Qiagen in 2015. Prior to that he was senior executive VP of worldwide commercial operations at BioMérieux, where he also managed investor relations for the greater China region.

Bernard is "an outstanding leader who has performed impressively while guiding Qiagen through a period of significant change since taking on this role on an interim basis in October 2019," Håkan Björklund, chairman of Qiagen's supervisory board, said in a statement. "He is a strong and proven leader with extensive industry expertise and deep customer relationships. Most important, he has shown the energy and skill to drive Qiagen forward and has been a key leader in achieving the agreement for Qiagen to be acquired by Thermo Fisher Scientific in a transaction that remains on track for completion in the first half of 2021."

Mar 24, 2020

Scipher Medicine: Slava Akmaev

Scipher Medicine has appointed Slava Akmaev as its chief technology officer, a role that includes overseeing the company's data science and technology teams, ensuring efficient data on-boarding, quality control, and rapid analytics across Scipher's pipeline of precision diagnostics.

Akmaev is a leader in applying high-throughput molecular technology, machine learning, artificial intelligence, and data analysis within the life sciences and healthcare industry, and routinely publishes in the peer-reviewed scientific literature. Prior to joining Scipher, he was the senior vice president and chief analytics officer at Berg, where he cofounded and led Berg Analytics. Prior to that he helped commercialize four molecular diagnostic tests at Genzyme Genetics. 

Mar 23, 2020

Myriad Genetics: Louise Phanstiel, John Henderson

Myriad Genetics' board of directors has nominated Louise Phanstiel as its new chair. Phanstiel has served as a director at Myriad since September 2009, has chaired the audit committee and been a member of the nominating and governance committee. She has held various positions at insurer Anthem, and was a partner at PricewaterhouseCoopers. Phanstiel has previously served on the boards of Verastem and Inveresk Research Group.

John Henderson, meanwhile, has resigned as chair of Myriad's board, but will continue to serve as a director. "This change in the leadership of the board is a reflection of the changing environment in which Myriad Genetics operates," Henderson said in a statement. "While the company remains focused on providing critical health care information for the patient, there also is a need to ensure optimization of the processes, which ensure efficient delivery of results, while managing business operations effectively."

Mar 17, 2020

Roche: Jörg Duschmalé, Patrick Frost

Roche has elected Jörg Duschmalé and Patrick Frost to its board of directors, while Andreas Oeri and John Bell have stepped down after 24 and 19 years on the board, respectively. Oeri was the representative of the current shareholder pool.

Duschmalé is a fifth-generation descendant of Roche's founder, and he was a postdoctoral researcher in oligonucleotide chemistry at Roche from 2015 to 2018. Frost has worked at life insurance company Swiss Life in Zurich since 2006, first as Group Chief Information Office and now as Group CEO. He previously served as the global head of fixed income investment at Winterthur Insurance.
Mar 17, 2020

Thrive Earlier Detection: Matt Franklin, Sarah Larson, Semi Trotto

Thrive Earlier Detection has announced the appointment of Matt Franklin as its chief commercial officer, the appointment of Sarah Larson to its board of directors, and Semi Trotto's promotion to chief people officer.

Franklin holds more than 20 years of business, commercial, and strategic marketing experience in the diagnostics, life sciences, and technology industries. Most recently, he served as chief business officer at ArcherDx, where he was responsible for various business development activities. Prior to Archer, he held senior leadership roles at both Foundation Medicine and Boston Scientific.

Larson currently serves as partner and chief human resources officer at Third Rock Ventures where she is responsible for human resources and also provides guidance and counsel to the firm's portfolio companies, focusing on areas of human capital, leadership development, and culture creation. She has more than 20 years of experience in human resources and leadership development.

Trotto, a member of Thrive's founding management team, most recently served as senior vice president and head of human resources. Before joining Thrive, she held leadership positions in human resources at Editas Medicine, Baxalta, and Bristol-Myers Squibb. She has more than 20 years of experience in the field overall.

Mar 16, 2020

Oxford BioDynamics: Jon Burrows, Christian Hoyer Millar

Maryland-based Oxford BioDynamics has appointed Jon Burrows as group CEO, replacing Christian Hoyer Millar. Burrows currently works at consulting and clinical advisory firm Oncology Partners. He previously served as president and CEO of OncoPlex Diagnostics and as director of business development and interim head of Ventana Medical Systems' translational diagnostics business unit. After Roche acquired Ventana, Burrows served as director of pharma operations. 

Millar has served as OBD's CEO since cofounding the firm in 2007, and will now serve as executive chairman. 

Mar 13, 2020

NantHealth: Deanna Wise

NantHealth has named Deanna Wise to its board of directors. Wise serves as senior VP and CIO of Phoenix-based Banner Health. Prior to joining Banner a year ago, she was executive VP and CIO of Dignity Health, where she oversaw the implementation of a multi-site electronic health records system and a predictive analytics program.  

Mar 12, 2020

Sema4: Rachel Sherman

Genetic testing and informatics firm Sema4 has appointed Rachel Sherman to its board of directors.

Sherman is a former principal deputy commissioner of food and drugs at the US Food and Drug Administration. Her career at FDA spanned almost three decades and she oversaw HIV drug development, directed the Critical Path initiative, launched expedited review, and guided the establishment of the oncology center of excellence program.

She is currently a drug development, regulatory, and policy consultant at a firm she founded last year after retiring from FDA, and a lecturer at Harvard Medical School's Department of Population Medicine. She also serves on the board of Aptinyx, a pharmaceutical firm.

Sherman holds an MD from Mount Sinai School of Medicine and a master's degree in public health from Johns Hopkins University.

Mar 10, 2020

Thermo Fisher Scientific: Paul Parker

Paul Parker will join Thermo Fisher Scientific as VP of strategy and corporate development, starting April 15. He will join the company from Goldman Sachs, where he was co-chairman of global mergers & acquisitions and a member of the firm's partnership committee. Previously, he held operating and client relationship roles at Goldman Sachs, Barclays, Lehman Brothers, and JP Morgan. Parker has degrees from Harvard Business School and from the University of North Carolina at Chapel Hill.

Mar 10, 2020

Biodesix: Kieran O'Kane, Bobbi Coffin

Biodesix has announced a realignment of its commercial executive team. Effective immediately, current head of strategic marketing Kieran O'Kane will become the company's chief commercial officer, while Bobbi Coffin, currently chief marketing officer, will become the firm's chief growth officer.

After joining the company in 2018, Biodesix said that O'Kane played a leading role in the successful acquisition of Integrated Diagnostics and Oncimmune's laboratory and incidental pulmonology nodule malignancy test, proving instrumental in the subsequent commercial launch of what are now the Nodify XL2 and Nodify CDT tests. He previously worked at various other companies, including NanoString Technologies, Bristol Myers Squibb, and Roche.

Coffin joined Biodesix in 2015 from Exact Sciences where she was VP of commercial marketing and strategy. Prior to that role, she held leadership positions at Precision Therapeutics and Cytyc/Hologic.

Mar 10, 2020

Fulgent Genetics: Brandon Perthuis

Fulgent Genetics has promoted Brandon Perthuis to chief commercial officer from VP of commercial operations. He will continue to lead the company's global sales organization and commercialization effort and will report to CEO Ming Hsieh. Perthuis came to Fulgent in 2017. He carries 16 years of experience in clinical genetics, including a stint as VP of sales and marketing at Baylor Genetics.

Mar 09, 2020

Centogene: Dirk Ehlers

Centogene said that COO and President Dirk Ehlers will leave the company for personal reasons after the annual general meeting in June. He has been a member of the executive management board for two years. He joined Centogene in April 2018 from Hill-Rom Holdings. Prior to that, he was CEO of Eppendorf, and he held management positions at Roche, Fresenius Kabi, Olympus Optical, and Evotec.

Mar 09, 2020

Genomics: Mitchell Harris, Gil McVean

Mitchell Harris has joined UK company Genomics as chief strategy officer. He also became a member of the firm's executive leadership team. Harris comes to Genomics from Abcam, where he was global head of emerging business lines. Before that, he was a principal at QuantumBlack, the AI and advanced analytics arm of McKinsey & Company, as well as engagement manager at McKinsey.

In addition, Gil McVean has taken on the role of acting chief operating officer at Genomics, in addition to his post as chief information officer and a member of the executive leadership team.  

Mar 06, 2020

Pacific Biosciences: Christian Henry, Mike Hunkapiller, William Ericson

Pacific Biosciences has appointed Christian Henry to serve as chairman of its board of directors, effective immediately.

PacBio said in a statement it was separating the chairman and CEO roles "in alignment with best practices." Mike Hunkapiller, the previous chairman, will continue to serve as president and CEO and will remain on the board. William Ericson of Wildcat Venture Partners will step down as lead independent director but will also continue to serve on the board.

Henry was previously executive VP and chief commercial officer at Illumina. He joined the board in July 2018.

PacBio will provide Henry an annual retainer of $35,000 as well as options to purchase 35,000 shares of common stock.

Mar 02, 2020

BC Platforms: Karen Tay Koh

BC Platforms has named Karen Tay Koh to its board of directors. A former deputy CEO of the publicly owned Singapore Health Services provider network, Koh is a senior advisor to Dubai-based private equity firm TVM Capital Healthcare Partners and sits on numerous other boards, including that of Danish emergency medical firm Falck. BC Platforms said that she will work closely with the company's newly established Singapore office to serve the Asia-Pacific region. 

Mar 02, 2020

PerkinElmer: Michel Vounatsos

PerkinElmer has appointed Michel Vounatsos to its board of directors, effective March 1. He is currently CEO of Biogen. Before that, he was at Merck, where he held several leadership positions, including president of the Primary Care Customer Business Line and Merck Customer Centricity. Earlier in his career, he held management positions at Ciba-Geigy. 

Feb 28, 2020

InformedDNA: Paul Danao, Jacqueline Kosecoff

Genetic services provider InformedDNA has named Paul Danao as chief growth officer, and appointed Jacqueline Kosecoff to its board as an independent director.
 
Danao previously held senior leadership roles at several healthcare technology and service companies including BlueCross BlueShield Association, AIM Specialty Health, and Healthcare Payment Specialists.
 
Kosecoff is a managing partner at Moriah Partners, and senior advisor at Warburg Pincus. Previously she served as a senior executive with UnitedHealth Group-PacifiCare, where she was CEO of OptumRx. She also was founder, president, and COO of Protocare, and prior to that served as professor of medicine and public health at the University of California, Los Angeles.
Feb 26, 2020

Thermo Fisher Scientific: Marc Casper, Jim Manzi, Thomas Lynch

Thermo Fisher Scientific's board of directors has elected Marc Casper its chairman, effective immediately. Casper, who is the company's president and CEO, succeeds Jim Manzi, who will continue to serve as a director on Thermo Fisher's board. Manzi has been a director at the company since May 2000 and was chairman of the board for 15 years. Also, Thomas Lynch has been elected as lead independent director, effective immediately. He has been a board member since May 2009. 

Feb 25, 2020

Centogene: Vaibhav Joshi

Centogene has named Vaibhav Joshi to the newly created role of chief data officer. He joins the company from Virgin Care, which provides health and social care services in the UK. He was chief data officer there. Before that Vaibhav was clinical informatics director at the Private Healthcare Information Network and clinical analytics lead at Ramsay Health Care UK. 

Pages

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.